Duplicated membrane estrogen receptors in the European sea bass (Dicentrarchus labrax): Phylogeny, expression and regulation throughout the reproductive cycle

The numerous estrogen functions reported across vertebrates have been classically explained by their binding to specific transcription factors, the nuclear estrogen receptors (ERs). Rapid non-genomic estrogenic responses have also been recently identified in vertebrates including fish, which can be mediated by membrane receptors such as the G protein-coupled estrogen receptor (Gper). In this study, two genes for Gper, namely gpera and gperb, were identified in the genome of a teleost fish, the European sea bass. Phylogenetic analysis indicated they were most likely retained after the 3R teleost-specific whole genome duplication and raises questions about their function in male and female sea bass. Gpera expression was mainly restricted to brain and pituitary in both sexes while gperb had a widespread tissue distribution with higher expression levels in gill filaments, kidney and head kidney. Both receptors were detected in the hypothalamus and pituitary of both sexes and significant changes in gpers expression were observed throughout the annual reproductive season. In female pituitaries, gpera showed an overall increase in expression throughout the reproductive season while gperb levels remained constant. In the hypothalamus, gpera had a higher expression during vitellogenesis and decreased in fish entering the ovary maturation and ovulation stage, while gperb expression increased at the final atresia stage. In males, gpers expression was constant in the hypothalamus and pituitary throughout the reproductive cycle apart from the mid- to late testicular development stage transition when a significant up-regulation of gpera occurred in the pituitary. The differential sex, seasonal and subtype-specific expression patterns detected for the two novel gper genes in sea bass suggests they may have acquired different and/or complementary roles in mediating estrogens actions in fish, namely on the neuroendocrine control of reproduction.info:eu-repo/semantics/publishedVersio

Peculiar objects towards 3FGL J0133.3+5930: an eclipsing Be star and an active galactic nucleus

Aims. We aim to contribute to the identification of unassociated gamma-ray sources in the galactic plane in order to enlarge the currently known population of gamma-ray binaries and related systems, such as radio emitting X-ray binaries and microquasars. These objects are currently regarded as excellent test beds for the understanding of high energy phenomena in stellar systems. Methods. Potential targets of study are selected based on cross-identification of the 3rd Fermi Large Area Telescope catalogue with historical catalogues of luminous stars often found as optical counterparts in known cases. Follow-up observations and analysis of multi-wavelength archival data are later used to seek further proofs of association beyond the simple positional agreement. Results. Current results enable us to present here the case of the Fermi source 3FGL J0133.3+5930 where two peculiar objects have been discovered inside its region of uncertainty. One of them is the star TYC 3683-985-1 (LS I +59 79) whose eclipsing binary nature is reported in this work. The other one is the X-ray source SWIFT J0132.9+5932, that we found to be a likely low-power Active Galactic Nucleus at z = 0:1143 \pm 0:0002. If this second object is of blazar type, it could easily account for the observed gamma-ray photon flux. However, this is not confirmed at present, thus rendering still open the star system TYC 3683-985-1 as an alternative counterpart candidate to the Fermi source.Comment: 8 pages; 10 figures; accepted for publication in Astronomy & Astrophysic

Efectos de la restricción calórica sobre el inicio de la pubertad y la calidad del esperma en la lubina europea (Dicentrarchus labrax)

Ponencia presentada en el XIII Congreso Nacional de Acuicultura celebrado en Barcelona del 21 al 24 de noviembre de 2011.This study reports the effects induced by a long fasting protocol on the reproductive performance of male sea bass during the first reproductive season. Two different treatments of food deprivation were carried out from July to March, one feed 1/4 and another feed 1/8 of the ration given to the control group (1/4C, 1/8C and C). Both restricted feed regimes resulted in a deep impact over the weight, length and growth rate indexes. Also, the fat visceral index decreased dramatically in November in both feed restricted groups (1/4C and 1/8C). Interestingly, both restricted and controls had similar gonadosomatic index values in November (IGS= 0.4-0.7%). Moreover, the histological analysis revealed the presence of a high number of death cell bodies in testis of those animals kept under both restricted feed regimes. Furthermore, we evaluated the sperm quality along the reproductive season (December-March) and it was shown that a long-term fasting affects sperm quality parameters of pubertal male sea bass such as, density (nº spz cells/ml) and quantity (ml/kg wt), although no differences were observed in motility (µm/seg). Additionally, no statically differences in 11KT plasma levels were observed among experimental groups. Our study evidences that a shortage on energy store is not enough to abolish partially or totally the puberty onset of prepubertal male sea bass.Proyecto Europeo LIFECYCLE (FP7-222719-1) y Generalitat Valenciana (PROMETEO/2010/003). S.E. disfrutó de una beca JAE-Predoc CSIC y M.S. disfrutó de una beca CIHEAM.Peer Reviewe

Apoyo social formal en colectivos con dificultades de inserción laboral

IX Jornades de Foment de la Investigació de la FCHS (Any 2003-2004

High In-content InGaN layers synthesized by plasma-assisted molecular-beam epitaxy: growth conditions, strain relaxation and In incorporation kinetics

We report the interplay between In incorporation and strain relaxation kinetics in high-In-content InxGa1-xN (x = 0.3) layers grown by plasma-assisted molecular-beam epitaxy. For In mole fractions x = 0.13-0.48, best structural and morphological quality is obtained under In excess conditions, at In accumulation limit, and at a growth temperature where InGaN decomposition is active. Under such conditions, in situ and ex situ analysis of the evolution of the crystalline structure with the growth thickness points to an onset of misfit relaxation after the growth of 40 nm, and a gradual relaxation during more than 200 nm which results in an inhomogeneous strain distribution along the growth axis. This process is associated with a compositional pulling effect, i.e. indium incorporation is partially inhibited in presence of compressive strain, resulting in a compositional gradient with increasing In mole fraction towards the surface

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Pembrolizumab; Non-small-cell lung cancerPembrolizumab; Cáncer de pulmón de células no pequeñasPembrolizumab; Càncer de pulmó de cèl·lules no petitesClinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials.gov identifier: NCT02578680). Eligible patients with previously untreated metastatic nonsquamous non-small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator's choice of carboplatin/cisplatin for four cycles, followed by maintenance pemetrexed until disease progression or unacceptable toxicity. Primary end points were overall survival (OS) and progression-free survival (PFS). Among 616 randomly assigned patients (n = 410, pembrolizumab plus pemetrexed-platinum; n = 206, placebo plus pemetrexed-platinum), median time from random assignment to data cutoff (March 8, 2022) was 64.6 (range, 60.1-72.4) months. Hazard ratio (95% CI) for OS was 0.60 (0.50 to 0.72) and PFS was 0.50 (0.42 to 0.60) for pembrolizumab plus platinum-pemetrexed versus placebo plus platinum-pemetrexed. 5-year OS rates were 19.4% versus 11.3%. Toxicity was manageable. Among 57 patients who completed 35 cycles of pembrolizumab, objective response rate was 86.0% and 3-year OS rate after completing 35 cycles (approximately 5 years after random assignment) was 71.9%. Pembrolizumab plus pemetrexed-platinum maintained OS and PFS benefits versus placebo plus pemetrexed-platinum, regardless of programmed cell death ligand-1 expression. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations

Sistema accesible, interoperable y ubicuo para el acceso a las nuevas tecnologías por parte de las personas con necesidades especiales

The possibility to access communication and information is indispensable to achieve equality of opportunities and full citizenship participation. However, people with some sort of handicap find themselves with environments, services and products inaccessible for them and making their daily life more difficult. Communication barriers are those obstacles that prevent these people to access information. Advance in information technologies and communications, diminishing in hardware costs and information transmission rates allows us today to develop tools that give people with special needs access to new technologies. CIM Fundation has been collaborating in the development of an accessible and ubiquitous platform for people with special needs as part of his participation in the INREDIS project within the CENIT Program. The objective of this project is the development of a system that offers a multiplatform, adaptive and natural interface that responds with intelligence to the user’s needs. The platform has been developed with a Software Oriented Architecture (SOA) and within Software as a Service model (SaaS).Peer ReviewedPostprint (published version

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Inmunoterapia dual; Ipilimumab; NivolumabImmunoteràpia dual; Ipilimumab; NivolumabDual immunotherapy; Ipilimumab; NivolumabBackground To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. Patients and methods Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. Results With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. Conclusions With a 2-year minimum follow-up, nivolumab plus ipilimumab with two cycles of chemotherapy provided durable efficacy benefits over chemotherapy with a manageable safety profile and remains an efficacious first-line treatment of advanced non-small-cell lung cancer.This work was supported by Bristol Myers Squibb (Princeton, New Jersey) (no grant number). Authors received no financial support or compensation for publication of this manuscript